Skip to content

Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer

Project ACCESS: A Pilot Randomized Controlled Trial of a Navigator Delivered Model to Enhance Access to Supportive Services for Women of Color With Metastatic Breast Cancer

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06405828
Acronym
ACCESS
Enrollment
67
Registered
2024-05-09
Start date
2024-05-01
Completion date
2026-11-30
Last updated
2025-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Breast Cancer, Stage IV Breast Cancer AJCC V7

Brief summary

Black and Latina women experience disparities in supportive and palliative care access and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and acceptability of a community navigator delivered supportive care intervention for historically underserved populations of women with metastatic breast cancer.

Detailed description

Primary Objectives: 1. Establish the feasibility and acceptability of an adapted navigator delivered supportive care model called ACCESS to address supportive care needs for Black and Latina women with Metastatic Breast Cancer. 2. Determine the potential impact of ACCESS on cancer related distress, symptom burden, and utilization of supportive care services. OUTLINE: Participants (N=60) are randomized to 1 of 2 groups: GROUP 1/Intervention Group: Participants complete 6 individualized behavioral/educational sessions focused on social determinants of health and supportive care with a trained community navigator followed by monthly phone call check ins for 4 months. Participants complete questionnaires over the phone with a research coordinator at baseline, 6 and 9 months. GROUP 2/Attention Control group: Participants complete 6 phone calls with a research coordinator focused on supportive care resources followed by monthly phone call check ins for 4 months. Participants complete questionnaires over the phone with a research coordinator at baseline, 6 months and 9 months. .

Interventions

BEHAVIORALACCESS Supportive Care

ACCESS Supportive Care includes: 1. Coaching sessions: 6 one-hour weekly Community Navigator led supportive and early palliative care health coaching sessions. Sessions will be hybrid (in-person or virtual) per participant preference. 2. Monthly check-in: Monthly check-ins (\ 5-10 minutes) about their supportive care and social determinants of health needs over 16 weeks. 3. Scheduling of outpatient supportive oncology appointment if interested. 4. Community linkage: Warm hand offs and connection to community resources to enhance access to support groups, educational workshops, and healthy lifestyle services.

BEHAVIORALPhone sessions

6 weekly phone sessions, approximately 10 minutes in length each, to review breast cancer and supportive and palliative care resources in NYC and online. The 6 weekly phone sessions will include the topics discussed in the intervention arm but will be informational in nature. The phone sessions will be followed by monthly check-ins (\ 5 minutes) to review and answer questions about the resources for the duration of 16 weeks.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women ≥18 years of age * English and/or Spanish speaking * Self-identify as Latina and/or African American/Black * Ability to understand and the willingness to sign a written informed consent * Stage IV breast cancer diagnosis, no time component

Exclusion criteria

* Moderate to severe cognitive impairment * receiving inpatient hospice care * if patients were previously enrolled in Aim 1 and Aim 2 * currently working with a community navigator

Design outcomes

Primary

MeasureTime frameDescription
Number of participants recruitedat 9 monthsAcceptability evaluates if patients accept the intervention through the ability to recruit 60 participants in 1.5 years and a \<20% dropout rate at 9 months
Number of participants remaining in studyat 9 monthsAcceptability evaluates if patients accept the intervention through a \<20% dropout rate at 9 months
Number of times navigator communicates with oncology team9 monthsIntegration evaluates if the navigator can communicate with the supportive oncology and medical oncology team at least 80% of the time.
Number of times participants connect to resources9 monthsIntegration evaluates if at least 80% of patients can connect to community and clinical resources.
Number of visits6 monthsPracticality evaluates if the navigator is able to deliver the intervention in person or virtual. Successful practicality benchmarks include \> 80% of the visits conducted.
Number of phone calls9 monthsPracticality evaluates if the navigator is able to deliver the intervention in person or virtual. Successful practicality benchmarks include \>80% of follow up phone calls conducted.
Number of visits conducted according to the ACCESS manual9 monthsFidelity: This is indicated if \>80% of the visits are conducted according to the ACCESS manual.
Change in The Impact of Event Scale - Revised (IES-R) scoresBaseline and 9 monthsCancer-related distress will be measured through the Impact of Event Scale - Revised (IES-R) is a 22-item instrument to assess distress. Each item is scored 0-4, with full scale from 0-22. Higher scores indicate greater severity of symptoms related to distress. Efficacy assessed by mean differences at 9 months as compared to baseline.
Change in The Memorial Symptom Assessment Scale (MSAS)Baseline and 9 monthsSymptom Burden will be measured through the Memorial Symptom Assessment (MSAS) is a 32 item instrument. Each item is scored from 0 to 4 with full scale from 0-128. A higher score indicates a greater level of symptom distress.

Countries

United States

Contacts

Primary ContactMelissa Mazor
melissa.mazor@mountsinai.org(510) 418-8642

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026